Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

Sun Yat-sen University

Status: Unknown

Conditions: Portal Vein, Cavernous Transformation Of

Treatments: Drug: Montelukast

Study type: Observational

Funder types: Other

Identifiers

NCT02505113

CTPVDORNO3HSYSU

Details and patient eligibility

About

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

Full description

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.

Enrollment: 150 estimated patients

Sex: All

Ages: 1 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with CTPV.

Exclusion criteria

• Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Trial design

150 participants in 2 patient groups

CTPV without Montelukast

Description:

Patients with CTPV do not receive the treatment of Montelukast.

CTPV treated with Montelukast

Description:

Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).

Treatment:

Drug: Montelukast